Introduction
============

The number of opioid prescriptions in the USA has risen dramatically over the past 25 years, increasing from 76 million in 1991 to 259 million in 2012.[@b1-jpr-9-129] With the rise in opioid prescriptions, the abuse and diversion of prescription opioids has increased,[@b2-jpr-9-129] and prescribers face the challenge of balancing the risks and potential benefits of these medications.[@b3-jpr-9-129] As more than 40% of opioid prescriptions are written by general or family practitioners,[@b4-jpr-9-129] the opioid prescribing patterns of this group of health care professionals have an important influence on the general public health of US residents.

A majority of primary care providers prescribe opioids for pain.[@b5-jpr-9-129]--[@b9-jpr-9-129] However, many primary care providers find opioid prescribing a significant challenge. For example, many report that their formal training about opioid prescribing was inadequate.[@b5-jpr-9-129],[@b6-jpr-9-129],[@b10-jpr-9-129]--[@b12-jpr-9-129] Furthermore, they report concerns about medication side effects, regulatory scrutiny, addiction, and opioid misuse.[@b7-jpr-9-129],[@b8-jpr-9-129],[@b10-jpr-9-129],[@b12-jpr-9-129]--[@b16-jpr-9-129] A recent systematic review found that most physicians do not follow all recommendations regarding safe opioid prescribing, and significant knowledge gaps were identified.[@b17-jpr-9-129] Primary care providers who have received pain management education after formal training reported the greatest level of confidence with prescribing opioids for chronic pain.[@b18-jpr-9-129]

Few surveys exist that assess the knowledge of nonpain specialty providers about the management of chronic pain. The KnowPain-50 survey was developed specifically to assess pain management education among physicians.[@b19-jpr-9-129] While the survey covers a broad range of chronic pain topics frequently encountered in the primary care setting, at least one-third of the test specifically addresses opioid prescribing. Thus, the purpose of this study was to assess the knowledge about prescribing opioids for chronic pain among nonpain specialty providers seeking pain-focused continuing medical education (CME).

Methods
=======

Study participants
------------------

The participants in this study were health care providers with prescription privileges seeking CME about pain management. All providers were nonpain specialists attending a course entitled "Pain Medicine for the Non-Pain Specialist". Eligible participants included physicians, physician assistants, and nurse practitioners. A total of 219 health care providers attended the CME course and 131 (60%) completed the KnowPain-50 survey. Three surveys were excluded due to missing data, and the final cohort comprised 128 surveys. Following submission to Mayo Foundation Institutional Review Board (IRB) for ethics approval, it was determined that the research activity did not require IRB review in accordance with the Code of Federal Regulations (45 CFR 46).[@b20-jpr-9-129] The Mayo Foundation Institutional Review Board did not require written informed consent be obtained from the study participants because all data was de-identified and participation was voluntary.

Study setting
-------------

The CME conference was held in March 2013 at a conference center over the course of 3 days; 30-minute lectures were delivered from 8 am to 12:30 pm. Each lecturer presented information using slides projected on a centrally located screen, and participants were allowed to ask questions after each lecture. The conference was sponsored by a tertiary referral medical center's CME department.

Upon commencement of the conference, the attendees were asked to complete the KnowPain-50 survey. The KnowPain-50 survey was administer in paper format, and all attendees were given adequate time to complete the survey.

Data collection
---------------

### Demographics and practice characteristics

Participants were asked to report basic demographic data, including age, sex, years of practice, and professional training (eg, physician, physician assistant/nurse practitioner).

### KnowPain-50

The KnowPain-50 survey comprised 50 questions.[@b19-jpr-9-129] Eighteen of the 50 questions were related to opioid management and the remaining 32 questions were related to general knowledge about pain medicine. The focus of each opioid question was further categorized as either medicolegal (n=7) or clinical (n=11). All medicolegal questions contained the words or phrases "investigated", "illegal", "not lawful", "state and federal requirements", or "federal regulations". The clinical questions pertained to the clinical management of pain with opioids.

The survey was scored according to the approach described by Harris et al.[@b19-jpr-9-129] Five questions used a multiple-choice single response format; correct single responses were awarded 5 points and incorrect single responses were awarded 0 points. One of the five multiple-choice questions was a clinical question about opioids ("By far the most common adverse side effect of opioid therapy is:"). The remaining 45 questions were answered using a Likert scale ranging from 1 to 6, where 1= strongly agree; 2= agree; 3= somewhat agree; 4= somewhat disagree; 5= disagree; 6= strongly disagree. The correct response for 25 of the Likert questions was the negative (strongly disagree, disagree, somewhat disagree), and the correct response for the remaining 20 Likert questions was the affirmative (strongly agree, agree, somewhat agree). All responses to the Likert questions were converted to a 0- to 5-point scale, where the "strongly agree" or "strongly disagree" correct responses were awarded 5 points, and all other responses were awarded a sequentially diminishing number of points. For example, for questions where the correct response was the negative, 5 points were awarded for the response "6= strongly disagree", 4 points were awarded for the response "5= disagree", 3 points were awarded for the response "3= somewhat disagree", and so on until 0 points were awarded for the response "6= strongly agree". Alternatively, for questions where the correct response was the affirmative, 5 points were awarded for the response "1= strongly agree", 4 points were awarded for the response "5= agree", 3 points were awarded for the response "3= somewhat agree", and so on until 0 points were awarded for the response "6= strongly disagree". The maximum possible points for the 50-item survey were 250.

Statistical analysis
--------------------

The mean and standard deviation (±) (age, years in practice), or proportion (sex) were reported for the demographic and practice characteristics. For the Likert questions, test responses awarded 3--5 points were categorized as correct responses and test responses awarded 0--2 points were categorized as incorrect. The proportion of correct responses was determined for the entire 50-item survey. The proportion of correct responses for the 32 nonopioid questions and 18 opioid questions were compared using the chi-square (*χ*^2^) test. The proportion of correct responses for the eleven clinical opioid questions and seven medicolegal opioid questions were compared in a similar manner. The correlations between the demographic (age, sex) and practice characteristics (years in practice) and the proportion of correct responses to the entire 50-item survey, 32 nonopioid questions, and 18 opioid questions were assessed using Spearman's correlation coefficient (ρ). Two-sided tests were used in all analyses, and the level of significance for all statistical tests was set at 0.05. Statistical analyses were carried out using the IBM SPSS Statistics (version 21.0, IBM Corporation, Armonk, NY, USA).

Results
=======

Demographic and practice characteristics
----------------------------------------

The demographic and practice characteristics are shown in [Table 1](#t1-jpr-9-129){ref-type="table"}. Physicians were predominantly male (68%), whereas nonphysicians were predominantly female (80%). Physicians were also older (51.8±11.4 years) compared with nonphysicians (39.6±10.3 years) (*P*\<0.001).

KnowPain-50 responses
---------------------

[Table 2](#t2-jpr-9-129){ref-type="table"} shows the frequency of responses to the 32 nonopioid questions. [Table 3](#t3-jpr-9-129){ref-type="table"} shows the frequency of responses to the seven medicolegal and eleven clinical opioid questions.

The proportion of correct responses to the entire 50-item survey was 72%. The proportion of correct responses to the 32 nonopioid questions was 74%, and the proportion of correct responses to the 18 opioid questions was 69% (*χ*^2^=13.5, *P*\<0.001). Similarly, the proportion of correct responses to the seven medicolegal opioid questions was 74%, and the proportion of correct responses to the eleven clinical opioid questions was 67% (*χ*^2^=12.1, *P*\<0.001).

No significant correlations were found between the demographic (age, sex) or practice characteristics (years in practice) and the proportion of correct responses to the entire 50-item survey, the 33 nonopioid questions, or the 17 opioid questions (all Spearman's ρ\<13.0; all *P*\>0.1).

Discussion
==========

One of the main findings of this study was that nonpain specialists seeking CME content about pain medicine scored significantly lower on questions about opioids compared with nonopioid-related questions. When the focus of the opioid questions was further categorized as either medicolegal or clinical, the respondents scored significantly lower on the clinical compared with the medicolegal opioid questions.

The majority of respondents were confident in their ability to pass an investigation of their opioid prescribing practices and in their ability to find and understand state and federal requirements related to prescribing opioids. This is similar to findings by Wolfert et al,[@b16-jpr-9-129] who reported that 59% of Wisconsin physicians were not concerned about their opioid prescribing practices being investigated. However, over 40% of these physicians responded, "do not know" to specific questions about state and federal requirements, demonstrating poor applied knowledge about these requirements. In a separate survey of family medicine physicians, the levels of concern about addiction, diversion, dependence, regulatory scrutiny, and side effects due to opioid use were investigated.[@b8-jpr-9-129] In this group of physicians, the responses varied widely, although they tended to have less concerns for regulatory scrutiny and diversion compared with physical dependence and tolerance.[@b8-jpr-9-129]

On the KnowPain-50 survey, participants scored significantly lower on questions about opioids compared with nonopioid-related questions. More specifically, the proportion of correct scores ranged from 45% to 55% on several key clinically related opioid questions, including "Morphine-induced sedation is only a transient problem and will usually clear with continued use", "The presence of a physiologic basis for pain should be the primary factor when deciding to prescribe opiates", "I feel comfortable calculating conversion doses of commonly used opioids", "There is a limit or 'ceiling' to the dosage of pure agonist opioids \[...\] that can be used to control a patient's pain", and "I believe that analgesic tolerance to opioids usually limits long-term use". In a study by Lin et al,[@b21-jpr-9-129] 27% of geriatric and internal medicine physicians reported, "I do not know how to prescribe the correct dose" as a reason they hesitated to prescribe opioids. A similar study of Canadian family medicine physicians found that respondents scored higher than 40% on only two of nine knowledge-based questions about the use of prescription opioids.[@b13-jpr-9-129] A 2005 study of West Virginia family medicine physicians showed similar results in that respondents scored higher than 60% on only six of ten questions.[@b10-jpr-9-129] Likewise, a small study of primary care providers showed gaps in knowledge related to opioid prescribing where only 69% of questions were correctly answered.[@b12-jpr-9-129] These research findings are consistent with our current findings and support our previous observations[@b15-jpr-9-129] that knowledge about chronic pain has not been consistently associated with knowledge about the use of prescription opioids.[@b5-jpr-9-129],[@b7-jpr-9-129],[@b8-jpr-9-129]

While there have been few studies using objective tools to evaluate providers' knowledge before and after an educational intervention, recognized knowledge gaps[@b6-jpr-9-129],[@b10-jpr-9-129],[@b12-jpr-9-129],[@b13-jpr-9-129],[@b16-jpr-9-129],[@b17-jpr-9-129],[@b21-jpr-9-129] could be amenable to provider education. The observations from our survey study suggest that the educational interventions should be aimed toward enhancing knowledge about the clinical use of opioids compared with the medicolegal aspects of this form of pain therapy. This is particularly important as primary care providers consistently report low satisfaction with their formal training related to opioid management,[@b5-jpr-9-129],[@b10-jpr-9-129]--[@b12-jpr-9-129] and rate their clinical knowledge in this area as low.[@b6-jpr-9-129] A 2007 study of primary care providers by O'Rorke et al[@b18-jpr-9-129] found that physicians who were most comfortable managing chronic pain had received training after residency. This was recently confirmed by Lalonde et al[@b22-jpr-9-129] who reported that hours of CME focused on chronic pain were associated with higher scores on the KnowPain-50. These studies suggest that the postgraduate educational interventions may prove particularly effective for primary care providers who manage chronic pain. This supposition is supported by the findings of a recent prospective longitudinal study where primary care practitioners received education about the clinical management of chronic pain including management of patients receiving long-term opioid therapy.[@b23-jpr-9-129] Compared with baseline, practitioners at 1-year follow-up reported improvements in feeling sufficiently trained to manage patients receiving long-term opioid therapy, improved perceived confidence in prescribing opioids, and improvements in identifying patients at risk for opioid misuse.[@b23-jpr-9-129]

Limitations
===========

This study has limitations. Study participants were seeking CME regarding the management of chronic pain, and were potentially highly motivated to improve their knowledge about the management of chronic pain. Thus, selection bias could influence the generalization of the study observations to other populations of nonpain specialty providers. We did not differentiate by professional degree; thus, differences in professional training could have influenced the study findings. Recent advances in knowledge since publication of the KnowPain-50 suggests that the designated correct response to the question "Chronic opioid therapy has high risk of addiction in adults older than 40 years of age without history of substance abuse" may not be entirely accurate.[@b24-jpr-9-129]--[@b26-jpr-9-129]

Conclusion
==========

In summary, nonpain specialty providers demonstrated gaps in knowledge about opioid prescribing. Lower scores on clinically based questions may indicate an opportunity to provide focused educational content about this important area of clinical practice. The key observations from this study could be useful in designing future educational modules for nonpain specialty providers.
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###### 

Demographic and practice characteristics

  Characteristics                Total (n=128)   Physician (n=108)   NP/PA (n=20)   *P*-value
  ------------------------------ --------------- ------------------- -------------- -----------
  Sex, male/female, n            74/54           73/35               1/19           \<0.001
  Age, years, mean ± SD          49.5±12.0       51.8±11.4           39.6±10.3      \<0.001
  Years in practice, mean ± SD   18.2±0.37       20.4±11.4           8±6.5          \<0.001

**Abbreviations:** NP/PA, nurse practitioner/physician assistant; SD, standard deviation.

###### 

Proportion of correct responses to 32 nonopioid questions of the KnowPain-50 survey

  Nonopioid questions                                                                                             Strongly agree                                        Agree                                                Somewhat agree                                      Somewhat disagree                                   Disagree                                            Strongly disagree                                   Percent correct
  --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- -----------------
  Pain assessment includes pain level/emotionality/functionality                                                  53 (41%)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    70 (55%)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   4 (3%)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    0 (0%)                                              1 (1%)                                              0 (0%)                                              99%
  Early return to activities is a primary goal after onset of back pain                                           54 (42)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     57 (44)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    13 (10)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   3 (2)                                               1 (1)                                               0 (0)                                               95
  Antidepressants do not improve function in chronic pain patients                                                2 (2)                                                 4 (3)                                                3 (2)                                               22 (17)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   74 (58)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   23 (18)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   93
  Physical exercise worsens pain/function in patients with arthritis                                              2 (2)                                                 3 (2)                                                4 (3)                                               8 (6)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     53 (41)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   58 (45)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   92
  Pain complaints and disability always correlate                                                                 2 (2)                                                 3 (2)                                                6 (5)                                               15 (12)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   70 (55)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   32 (25)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   92
  Interdisciplinary treatment reduces disability/pain                                                             41 (32)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     59 (46)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    17 (13)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   5 (4)                                               4 (3)                                               2 (1)                                               91
  CBT is effective/apply early in the chronic pain treatment                                                      19 (14)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     46 (36)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    50 (40)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   11 (8)                                              2 (2)                                               0 (0)                                               90
  I understand surgical indications for acute herniated disc                                                      15 (12)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     49 (38)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    42 (33)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   15 (12)                                             5 (4)                                               2 (2)                                               88
  Gluteal myofascial pain and sciatica can have similar distribution                                              12 (9)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}      69 (54)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    29 (23)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   8 (6)                                               10 (8)                                              0 (0)                                               86
  Majority of cases, technology determines cause of chronic pain                                                  2 (2)                                                 3 (2)                                                16 (13)                                             26 (21)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   60 (47)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   21 (17)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   85
  Psychosocial factors predict back surgery outcomes better than physical characteristics                         12 (9)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}      41 (32)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    55 (43)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   11 (8)                                              9 (7)                                               0 (0)                                               84
  I understand how to diagnose and treat different types of pain                                                  6 (5)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}       44 (34)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    56 (44)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   12 (9)                                              5 (4)                                               4 (3)                                               83
  A placebo can be used to determine if pain is real                                                              2 (2)                                                 4 (3)                                                16 (13)                                             13 (10)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   62 (48)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   31 (24)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   82
  Nerve injuries can produce chronic neuropathic pain                                                             6 (5)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}       44 (34)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    55 (43)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   14 (11)                                             9 (7)                                               0 (0)                                               82
  I am comfortable taking pain history/ordering pain medications                                                  15 (12)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     44 (34)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    44 (34)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   19 (14)                                             4 (3)                                               2 (2)                                               80
  Pain out of proportion to the cause indicates drug abuse                                                        0 (0)                                                 1 (1)                                                28 (22)                                             29 (23)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   64 (50)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   6 (5)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     78
  MRI findings are consistently predictive of pain                                                                4 (3)                                                 12 (9)                                               14 (11)                                             15 (12)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   52 (41)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   31 (24)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   76
  I can assess function/activity status with careful questioning                                                  8 (6)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}       43 (34)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    46 (36)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   14 (11)                                             13 (10)                                             4 (3)                                               76
  Best therapy for fibromyalgia. Answer: aerobic exercise                                                         96 (75)[\*\*](#tfn3-jpr-9-129){ref-type="table-fn"}   --                                                   --                                                  --                                                  --                                                  32 (25)                                             75
  Distractibility from pain indicates absence of high pain intensity                                              0 (0)                                                 8 (6)                                                32 (24)                                             37 (29)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   46 (36)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   5 (4)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     69
  Patients may sleep in spite of severe pain                                                                      2 (2)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}       47 (36)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    41 (31)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   15 (12)                                             21 (16)                                             2 (2)                                               69
  Spinal cord/CNS generate neuropathic pain/sensitivity to touch                                                  11 (8)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}      54 (42)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    24 (19)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   13 (10)                                             23 (18)                                             3 (2)                                               69
  Daily chronic pain is unlikely to have a clear cause or cure                                                    11 (8)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}      36 (28)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}    39 (31)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   26 (20)                                             12 (9)                                              4 (3)                                               67
  High pain scores with minimal pathology indicates exaggeration                                                  3 (2)                                                 11 (9)                                               38 (30)                                             24 (19)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   45 (35)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   7 (5)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     60
  Diagnosis of diffuse pain with insomnia/fatigue/headache/dizziness. Answer: fibromyalgia                        76 (59)[\*\*](#tfn3-jpr-9-129){ref-type="table-fn"}   --                                                   --                                                  --                                                  --                                                  52 (41)                                             59
  Pain management with analgesics is effective in most patients                                                   2 (2)                                                 22 (17)                                              33 (26)                                             30 (24)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   33 (26)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   8 (6)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     56
  Changes in vital signs are reliable indicators of pain severity                                                 3 (3)                                                 13 (10)                                              42 (33)                                             33 (26)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   32 (25)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   5 (4)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     55
  Drugs with similar response to anticonvulsant/analgesic antidepressants for neuropathic pain. Answer: opioids   61 (48)[\*\*](#tfn3-jpr-9-129){ref-type="table-fn"}   --                                                   --                                                  --                                                  --                                                  67 (52)                                             48
  Back pain radiates down leg(s), EMG/NCS are usually useful for making a diagnosis                               1 (1)                                                 22 (17)                                              49 (38)                                             23 (18)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   30 (24)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   3 (2)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     44
  True statement regarding COX-2 inhibitors. Answer: no more effect than nonselective NSAIDs                      54 (42)[\*\*](#tfn3-jpr-9-129){ref-type="table-fn"}   --                                                   --                                                  --                                                  --                                                  74 (58)                                             42
  SSRIs are effective treatment for neuropathic pain                                                              7 (5)                                                 39 (31)                                              36 (28)                                             21 (16)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   20 (15)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   5 (4)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     35
  Anticonvulsants have established efficacy for musculoskeletal, nociceptive, or idiopathic pain                  4 (3)                                                 57 (45)                                              39 (30)                                             20 (15)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}   7 (5)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     1 (1)[\*](#tfn2-jpr-9-129){ref-type="table-fn"}     21

**Notes:**

Correct answer.

Multiple-choice single answer question where data for correct answer is shown in the "Strongly agree" column, and data for incorrect answer is shown in the "Strongly disagree" column.

**Abbreviations:** CBT, cognitive behavioral therapy; CNS, central nervous system; COX-2, cyclooxygenase-2; EMG/NCS, electromyography/nerve conduction studies; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin re-uptake inhibitors.

###### 

Proportion of correct responses to seven medicolegal and eleven clinical opioid questions of the KnowPain-50 survey

  Opioid questions                                                                                                   Strongly agree                                         Agree                                                Somewhat agree                                       Somewhat disagree                                   Disagree                                            Strongly disagree                                   Percent correct
  ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------ ---------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- -----------------
  **Medicolegal opioid questions**                                                                                                                                                                                                                                                                                                                                                                                                                
  Prescribing investigated, I am confident I would pass                                                              46 (37%)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}     43 (34%)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   28 (22%)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   6 (5%)                                              3 (2%)                                              0 (0%)                                              93%
  Unlawful to prescribe to a patient with known substance abuse                                                      3 (2)                                                  8 (6)                                                7 (5)                                                14 (11)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   66 (52)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   30 (23)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   86
  Federal law permits post-dated prescriptions                                                                       5 (4)                                                  21 (16)                                              4 (3)                                                14 (11)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   42 (33)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   42 (34)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   78
  I know how to find state, federal requirements                                                                     18 (14)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}      45 (35)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    22 (17)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    23 (18)                                             17 (13)                                             2 (2)                                               67
  Illegal to prescribe methadone unless addiction certified                                                          19 (15)                                                19 (15)                                              7 (6)                                                8 (6)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}     42 (33)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   32 (25)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   65
  I understand state, federal requirements                                                                           14 (11)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}      33 (26)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    32 (25)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    31 (24)                                             15 (12)                                             2 (2)                                               62
  Federal regulations limit the number of prescribed dosages                                                         8 (6)                                                  29 (23)                                              14 (11)                                              19 (15)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   46 (36)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   11 (9)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    60
  **Clinical opioid questions**                                                                                                                                                                                                                                                                                                                                                                                                                   
  The elderly cannot tolerate opioids                                                                                2 (2)                                                  5 (4)                                                8 (6)                                                18 (14)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   71 (55)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   24 (19)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   88
  Most common opioid adverse effect. Answer: constipation                                                            110 (86)[\*\*](#tfn6-jpr-9-129){ref-type="table-fn"}   --                                                   --                                                   --                                                  --                                                  18 (14)                                             86
  Long-term NSAIDs have higher risks than opioids                                                                    7 (5)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}        41 (32)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    47 (37)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    16 (13)                                             12 (9)                                              5 (4)                                               74
  No opioids for patients with a likely drug abuser profile                                                          5 (4)                                                  7 (5)                                                23 (18)                                              47 (37)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   38 (30)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   8 (6)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}     73
  No opioids for chronic pain of unknown cause                                                                       4 (3)                                                  9 (7)                                                22 (17)                                              36 (28)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   49 (39)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   7 (6)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}     72
  Chronic opioid therapy has high risk of addiction in adults \>40 years of age without history of substance abuse   1 (1)                                                  22 (17)                                              24 (19)                                              27 (21)                                             40 (31)                                             14 (11)                                             63
  Morphine-induced sedation usually clears with long-term use                                                        6 (5)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}        25 (20)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    39 (30)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    27 (21)                                             26 (20)                                             5 (4)                                               55
  Physiologic basis for pain should be primary factor for opioids                                                    2 (2)                                                  23 (18)                                              33 (26)                                              40 (31)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   26 (20)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   3 (2)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}     54
  There is a ceiling dose for opioids                                                                                8 (6)                                                  26 (20)                                              25 (20)                                              20 (16)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   36 (28)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   13 (10)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   54
  I am comfortable calculating                                                                                       12 (9)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}       21 (16)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    35 (27)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}    29 (23)                                             22 (17)                                             9 (7)                                               53
  conversion doses of opioids                                                                                                                                                                                                                                                                                                                                                                                                                     
  Analgesic tolerance limits long-term opioid use                                                                    4 (3)                                                  30 (23)                                              35 (27)                                              25 (20)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   32 (25)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}   2 (2)[\*](#tfn5-jpr-9-129){ref-type="table-fn"}     46

**Notes:**

Correct answer.

Multiple-choice single answer question where data for the correct answer given is shown in the "Strongly agree" column, and the data for the incorrect answer given is shown in the "Strongly disagree" column.

**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.
